The possibility that the Trump administration will implement
a structural change in healthcare policy has sparked debate about how
Alzheimer's care in the United States could be transformed. The proposal,
according to its proponents, focuses not on expanding the bureaucratic
apparatus or solely strengthening hospitals and insurers, but on redirecting
resources directly to patients.
The approach is based on a clear premise: giving greater
decision-making power to individuals and their families. Instead of public and
private funds being channeled primarily through large hospital systems,
government agencies, or administrative intermediaries, the idea is for funding
to go directly to the patient. Under this model, those facing an Alzheimer's
diagnosis could more freely choose which treatments, specialists, or support
services to access.
Proponents of this strategy believe that shifting
decision-making power from institutional structures to individuals would foster
competition, incentivize medical innovation, and reduce unnecessary costs. They
argue that, by having direct control over resources, families could prioritize
personalized therapies, home care, or clinical research programs that best suit
their needs.